Literature DB >> 11207650

Opsonizing antibodies (IgG1) up-regulate monocyte proinflammatory cytokines tumour necrosis factor-alpha (TNF-alpha) and IL-6 but not anti-inflammatory cytokine IL-10 in mycobacterial antigen-stimulated monocytes-implications for pathogenesis.

R Hussain1, H Shiratsuchi, M Phillips, J Ellner, R S Wallis.   

Abstract

Cachexia is one of the prominent features of advanced tuberculosis (TB) seen in association with increased expression of the monokine TNF-alpha. Several mycobacterial proteins, including PPD, stimulate TNF-alpha secretion from monocytes. Host factors that may play a role in cytokine expression from monocytes remain largely unknown. One such factor is the opsonizing antibodies. Monocytes have high-affinity receptors (FcgammaI and FcgammaIII) for IgG1 and IgG3 antibodies that mediate antigen uptake. We have reported selective up-regulation of IgG1 (which bind to Fcgamma receptors) in advanced TB and have recently shown the ability of PPD-specific IgG1 antibodies to augment TNF-alpha expression in PPD-stimulated monocytes. These observations have now been extended to other cytokines with semipurified fractions from secreted antigens of Mycobacterium tuberculosis (containing 30 kD and 58 kD) that were devoid of lipids, glycolipids and carbohydrates. In the presence of heat-inactivated TB plasma containing known amounts of antigen-specific IgG1 antibodies, these fractions induced significantly increased TNF-alpha, IL-6 and IL-10 secretion. Absorption of IgG1 with Protein 'A' removed the augmenting activity for TNF-alpha and IL-6 secretion from the TB plasma samples. In the case of IL-10, removal of IgG1 resulted in increased rather than decreased IL-10 secretion. These results suggest a possible pathogenic role for antibodies in TB by enhancing proinflammatory and blocking down-regulatory cytokines such as IL-10 cytokines during the chronic phase of TB.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11207650      PMCID: PMC1905980          DOI: 10.1046/j.1365-2249.2001.01439.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3.

Authors:  L S Schlesinger; C G Bellinger-Kawahara; N R Payne; M A Horwitz
Journal:  J Immunol       Date:  1990-04-01       Impact factor: 5.422

Review 2.  Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity.

Authors:  K Bendtzen
Journal:  Immunol Lett       Date:  1988-11       Impact factor: 3.685

3.  Activation of tuberculostatic macrophage functions by gamma interferon, interleukin-4, and tumor necrosis factor.

Authors:  I E Flesch; S H Kaufmann
Journal:  Infect Immun       Date:  1990-08       Impact factor: 3.441

4.  Induction of interleukin 1 and tumor necrosis factor by mycobacterial proteins: the monocyte western blot.

Authors:  R S Wallis; M Amir-Tahmasseb; J J Ellner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

5.  Expression of tumor necrosis factor in vitro by human mononuclear phagocytes stimulated with whole Mycobacterium bovis BCG and mycobacterial antigens.

Authors:  S E Valone; E A Rich; R S Wallis; J J Ellner
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

6.  Use of monoclonal antibodies to quantify subclasses of human IgG. II. Enzyme immunoassay to define antigen specific (anti-filarial) IgG subclass antibodies.

Authors:  R Hussain; R W Poindexter; E A Ottesen; C B Reimer
Journal:  J Immunol Methods       Date:  1986-11-20       Impact factor: 2.303

7.  Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon gamma-induced activation.

Authors:  I P Oswald; T A Wynn; A Sher; S L James
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

8.  Tumor necrosis factor alpha stimulates mycobactericidal/mycobacteriostatic activity in human macrophages by a protein kinase C-independent pathway.

Authors:  L E Bermudez; L S Young
Journal:  Cell Immunol       Date:  1992-10-15       Impact factor: 4.868

9.  Increase in tumor necrosis factor alpha- and interleukin-6-secreting cells in peripheral blood mononuclear cells from subjects infected with Mycobacterium tuberculosis.

Authors:  T Ogawa; H Uchida; Y Kusumoto; Y Mori; Y Yamamura; S Hamada
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

10.  Identification by two-dimensional gel electrophoresis of a 58-kilodalton tumor necrosis factor-inducing protein of Mycobacterium tuberculosis.

Authors:  R S Wallis; R Paranjape; M Phillips
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

View more
  13 in total

1.  Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis.

Authors:  Seon-Hee Cheon; Beate Kampmann; Amy G Hise; Manijeh Phillips; Ho-Yeon Song; Katherine Landen; Qing Li; Rhonda Larkin; Jerrold J Ellner; Richard F Silver; Daniel F Hoft; Robert S Wallis
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

2.  TNF-alpha antagonist therapy modify the tuberculin skin test response.

Authors:  Tulin Cagatay; Zeki Kilicaslan; Penbe Cagatay; Munevver Mertsoylu; Ziya Gulbaran; Reyhan Yildiz; Leyla Pur; Sevil Kamali; Ahmet Gul
Journal:  Rheumatol Int       Date:  2010-03-27       Impact factor: 2.631

3.  IgG1 antimycobacterial antibodies can reverse the inhibitory effect of pentoxifylline on tumour necrosis factor alpha (TNF-alpha) secreted by mycobacterial antigen-stimulated adherent cells.

Authors:  S M Thakurdas; Z Hasan; R Hussain
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

4.  Monocytes and neutrophils from tuberculosis patients are insensitive to anti-inflammatory effects triggered by the prototypic formyl peptide N-formyl-methionyl-leucyl-phenylalanine (FMLP).

Authors:  M Beigier-Bompadre; M Alemán; P Barrionuevo; M C Franco; C J Rubel; M Del C Sasiain; M S Palermo; E Abbate; M A Isturiz
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

5.  Portal Venous Thrombosis-Disseminated Tuberculosis in Rheumatoid Arthritis.

Authors:  Vasanthi Natarajan; Kevin John; David Jose; Pradeep Kalaiselvan; Ashok Kumar Das
Journal:  J Clin Diagn Res       Date:  2017-06-01

6.  Human T cell and antibody-mediated responses to the Mycobacterium tuberculosis recombinant 85A, 85B, and ESAT-6 antigens.

Authors:  Gilson C Macedo; Adriana Bozzi; Helena Rachel Weinreich; Andre Bafica; Henrique C Teixeira; Sergio C Oliveira
Journal:  Clin Dev Immunol       Date:  2010-12-29

7.  Cardioprotective Effects of Genistin in Rat Myocardial Ischemia-Reperfusion Injury Studies by Regulation of P2X7/NF-κB Pathway.

Authors:  Meng Gu; Ai-Bin Zheng; Jing Jin; Yue Cui; Ning Zhang; Zhi-Ping Che; Yan Wang; Jie Zhan; Wen-Juan Tu
Journal:  Evid Based Complement Alternat Med       Date:  2016-03-20       Impact factor: 2.629

8.  Biomarker changes associated with Tuberculin Skin Test (TST) conversion: a two-year longitudinal follow-up study in exposed household contacts.

Authors:  Rabia Hussain; Najeeha Talat; Firdaus Shahid; Ghaffar Dawood
Journal:  PLoS One       Date:  2009-10-14       Impact factor: 3.240

Review 9.  Venous Thromboembolic Disease in Chronic Inflammatory Lung Diseases: Knowns and Unknowns.

Authors:  George Keramidas; Konstantinos I Gourgoulianis; Ourania S Kotsiou
Journal:  J Clin Med       Date:  2021-05-11       Impact factor: 4.241

10.  Naturally produced opsonizing antibodies restrict the survival of Mycobacterium tuberculosis in human macrophages by augmenting phagosome maturation.

Authors:  Shashi Kant Kumar; Padam Singh; Sudhir Sinha
Journal:  Open Biol       Date:  2015-12       Impact factor: 6.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.